Divarasib
- Generic Name
- Divarasib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 2417987-45-0
- Unique Ingredient Identifier
- E6S21PVT91
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT06677957
- Locations
- 🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung CancerKRAS G12C Lung Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT06497556
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University Cancer & Blood Center, LLC, Athens, Georgia, United States
🇧🇷Hospital SÃrio-Libanês, Sao Paulo, São Paulo, Brazil
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 240
- Registration Number
- NCT05789082
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath